In part 1 we looked at Long-term kidney outcomes of semaglutide in ob*sity and cardiovascular disease in the SELECT trial, today well look at Semaglutide in patients with overw*ight or ob*sity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial As I mentioned in part 1, these will be long pieces so I have divided them into a summary, a deep dive, and then an analysis based on my framework for uses of GLP-1 drugs for actual health issues besides Type 2 Diabetes
[10] Hydroxocobalamin is available as a generic medication
Vitamin C also promotes the absorption of iron, while inhibiting its oxidation
GS Reduces Glucose Concentration and Increases Plasma Insulin Levels in a Dosage-Dependent Manner The glucose levels significantly declined over time in the treatment groups as compared to the positive control (Figure 1A)
There was no difference in the (low) numbers of confirmed hypoglycemia between DPP-4 inhibition and placebo and the occurrence of adverse events did not differ between the study groups except a slight increase in gastrointestinal adverse events in one of the studies (66)
(PubMed mirror for the open-access abstract.) Lake JE et al
